356 related articles for article (PubMed ID: 28293969)
1. Teduglutide for treatment of adult patients with short bowel syndrome.
Billiauws L; Bataille J; Boehm V; Corcos O; Joly F
Expert Opin Biol Ther; 2017 May; 17(5):623-632. PubMed ID: 28293969
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.
Jeppesen PB
JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):45S-52S. PubMed ID: 24615689
[TBL] [Abstract][Full Text] [Related]
3. Modern treatment of short bowel syndrome.
Jeppesen PB
Curr Opin Clin Nutr Metab Care; 2013 Sep; 16(5):582-7. PubMed ID: 23924950
[TBL] [Abstract][Full Text] [Related]
4. New approaches to the treatments of short bowel syndrome-associated intestinal failure.
Jeppesen PB
Curr Opin Gastroenterol; 2014 Mar; 30(2):182-8. PubMed ID: 24406477
[TBL] [Abstract][Full Text] [Related]
5. Treatment of adult short bowel syndrome patients with teduglutide.
Nørholk LM; Holst JJ; Jeppesen PB
Expert Opin Pharmacother; 2012 Feb; 13(2):235-43. PubMed ID: 22224470
[TBL] [Abstract][Full Text] [Related]
6. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B
Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
Thymann T; Stoll B; Mecklenburg L; Burrin DG; Vegge A; Qvist N; Eriksen T; Jeppesen PB; Sangild PT
J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):694-702. PubMed ID: 24399211
[TBL] [Abstract][Full Text] [Related]
10. Experience with teduglutide treatment for short bowel syndrome in clinical practice.
Pevny S; Maasberg S; Rieger A; Karber M; Blüthner E; Knappe-Drzikova B; Thurmann D; Büttner J; Weylandt KH; Wiedenmann B; Müller VA; Bläker H; Pascher A; Pape UF
Clin Nutr; 2019 Aug; 38(4):1745-1755. PubMed ID: 30145039
[TBL] [Abstract][Full Text] [Related]
11. Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects.
Vipperla K; O'Keefe SJ
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):683-7. PubMed ID: 24134154
[TBL] [Abstract][Full Text] [Related]
12. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
Yazbeck R
Curr Opin Mol Ther; 2010 Dec; 12(6):798-809. PubMed ID: 21154171
[TBL] [Abstract][Full Text] [Related]
13. Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.
Iturrino J; Camilleri M; Acosta A; O'Neill J; Burton D; Edakkanambeth Varayil J; Carlson PJ; Zinsmeister AR; Hurt R
JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1089-1095. PubMed ID: 26223941
[TBL] [Abstract][Full Text] [Related]
14. Teduglutide: a guide to its use in short bowel syndrome.
McKeage K
Clin Drug Investig; 2015 May; 35(5):335-40. PubMed ID: 25859983
[TBL] [Abstract][Full Text] [Related]
15. Teduglutide for the treatment of short bowel syndrome - a safety evaluation.
Kochar B; Herfarth HH
Expert Opin Drug Saf; 2018 Jul; 17(7):733-739. PubMed ID: 29848084
[TBL] [Abstract][Full Text] [Related]
16. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
[TBL] [Abstract][Full Text] [Related]
17. Teduglutide for the treatment of short bowel syndrome.
Ferrone M; Scolapio JS
Ann Pharmacother; 2006 Jun; 40(6):1105-9. PubMed ID: 16705029
[TBL] [Abstract][Full Text] [Related]
18. Gut hormones in the treatment of short-bowel syndrome and intestinal failure.
Jeppesen PB
Curr Opin Endocrinol Diabetes Obes; 2015 Feb; 22(1):14-20. PubMed ID: 25485516
[TBL] [Abstract][Full Text] [Related]
19. Emerging treatments for short bowel syndrome in adult patients.
Billiauws L; Joly F
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):241-246. PubMed ID: 30791759
[TBL] [Abstract][Full Text] [Related]
20. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ
Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
